A new experimental drug called Cotara is being investigated for the treatment of newly diagnosed and recurrent high grade brain tumors. This drug is an antibody which is combined with radioactive iodine. Cotara binds to proteins within the nucleus of necrotic (dead and dying) cells which are present in most malignant tumors. These cells may account for 50% of tumors and are primarily found at the center of the tumor. Cotara is given directly into the brain tumor as a continuous infusion through catheters. Once Cotara is delivered, it remains within the tumor and the attached radioactive iodine bombards the neighboring living tumor cells with radiation. Each successive treatment with Cotara kills more tumor cells and increases the necrotic regions, allowing it to be more effective with each treatment. Cotara has been used in patients who have previously received chemotherapy and/or radiation therapy.

			Showing Treatment 1 to 6 of 6		Location		Last Updated
	Details		Open-Label Dose Confirmation and Dosimetry Study of Interstitial 131I-chTNT-1/B mAb (Cotara®) for the Treatment of Recurrent Glioblastoma Multiforme		Philadelphia, PA USA		08/26/2007
	Details		Open-Label Dose Confirmation and Dosimetry Study of Interstitial 131I-chTNT-1/B mAb (Cotara®) for the Treatment of Recurrent Glioblastoma Multiforme		Charleston, SC USA		08/26/2007
	Details		Open-Label Dose Confirmation and Dosimetry Study of Interstitial 131I-chTNT-1/B mAb (Cotara®) for the Treatment of Recurrent Glioblastoma Multiforme		Philadelphia, PA USA		08/26/2007
	Details		Open-label, Dose Confirmation and Dosimetry Study of Interstitial 131-I chTNT-1/B mAb (Cotara®) for the Treatment of Recurrent Glioblastoma Multiforme (GBM)		Tustin, CA USA		07/31/2007
	Details		Iodine I 131 Monoclonal Antibody TNT-1/B (131I MOAB TNT-1/B), in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme		Detroit, MI USA		02/03/2006
	Details		An Open-label, Dose Confirmation and Dosimetry Study of Interstitial 131I-chTNT-1/B MAB (COTARA) for the Treatment of Glioblastoma Multiforme (GBM) at 1st of 2nd Relapse		Baltimore, MD USA		11/06/2005